Lead Story
Scientists decode two deadly flowers' chemistry, opening a sustainable path to new medicines
Researchers at Michigan State University and the Czech Academy of Sciences have identified all six enzymes wolfsbane and larkspur use to build atisinium, a complex compound in a family of chemicals long prized for pain relief, anti-malarial and anti-cancer potential but notoriously difficult to synthesize or extract safely given the plants' toxicity. By tracking thousands of genes across both species, the team pieced together the plants' full biosynthetic pathway, then transferred the genetic instructions into tobacco plants, which successfully reproduced the chemical assembly process as a kind of living factory. Published in Molecular Plant, the discovery means researchers can now grow and study these rare, hard-to-synthesize molecules in far larger and safer quantities than extracting them from the toxic source plants ever allowed, giving drug developers a practical route to explore compounds that have inspired medicine for millennia but resisted modern production.
Read more →Lead Story
Scientists decode two deadly flowers' chemistry, opening a sustainable path to new medicines
Researchers at Michigan State University and the Czech Academy of Sciences have identified all six enzymes wolfsbane and larkspur use to build atisinium, a complex compound in a family of chemicals long prized for pain relief, anti-malarial and anti-cancer potential but notoriously difficult to synthesize or extract safely given the plants' toxicity. By tracking thousands of genes across both species, the team pieced together the plants' full biosynthetic pathway, then transferred the genetic instructions into tobacco plants, which successfully reproduced the chemical assembly process as a kind of living factory. Published in Molecular Plant, the discovery means researchers can now grow and study these rare, hard-to-synthesize molecules in far larger and safer quantities than extracting them from the toxic source plants ever allowed, giving drug developers a practical route to explore compounds that have inspired medicine for millennia but resisted modern production.
A common dietary amino acid is shown to help the immune system fight tumors and infections
Rockefeller University cancer biologist Sohail Tavazoie and colleagues report in Cell that boosting dietary arginine — a common amino acid — quashed colon tumors in mice and protected them against flu and COVID-19, by restoring the immune system's ability to spot danger. The team found that low arginine levels stall production of MHC-I, a protein cells use to flag mutations or viral invaders to the immune system; feeding mice a high-arginine diet ramped MHC-I back up and sharply improved tumor and infection outcomes. Abnormally low arginine has previously been linked to colon cancer and several other diseases in humans, and Tavazoie cautioned it is far too early to know whether arginine supplements would have the same protective effect in people. Still, the mechanism is concrete enough that the team is now pursuing clinical studies of arginine supplementation, a comparatively simple intervention that could complement existing cancer and antiviral treatments if it holds up.
Read more →A common dietary amino acid is shown to help the immune system fight tumors and infections
Rockefeller University cancer biologist Sohail Tavazoie and colleagues report in Cell that boosting dietary arginine — a common amino acid — quashed colon tumors in mice and protected them against flu and COVID-19, by restoring the immune system's ability to spot danger. The team found that low arginine levels stall production of MHC-I, a protein cells use to flag mutations or viral invaders to the immune system; feeding mice a high-arginine diet ramped MHC-I back up and sharply improved tumor and infection outcomes. Abnormally low arginine has previously been linked to colon cancer and several other diseases in humans, and Tavazoie cautioned it is far too early to know whether arginine supplements would have the same protective effect in people. Still, the mechanism is concrete enough that the team is now pursuing clinical studies of arginine supplementation, a comparatively simple intervention that could complement existing cancer and antiviral treatments if it holds up.
Vanderbilt chemists build the first tools to control a hidden Alzheimer's target
Vanderbilt University researchers have synthesized VU6083859, the world's first selective compound able to inhibit TAOK-1, a poorly understood enzyme that drives the tau protein tangles characteristic of Alzheimer's disease, along with a second compound, VU6080195, that activates the entire TAOK protein family. The inhibitor demonstrated that blocking TAOK-1 prevents the hyperphosphorylation of tau that disrupts neurons' internal transport systems, while the activator gives scientists an unexpected new tool to probe TAOK biology broadly for the first time. Because no selective chemical tools for this target existed before, researchers had been unable to study TAOK-1's precise role in disease progression; with both an inhibitor and an activator now in hand, the field gains a matched pair of instruments to map the pathway in detail. More than seven million Americans currently live with Alzheimer's, and the Vanderbilt team says the compounds point toward a concrete new avenue for small-molecule drug development.
Read more →Vanderbilt chemists build the first tools to control a hidden Alzheimer's target
Vanderbilt University researchers have synthesized VU6083859, the world's first selective compound able to inhibit TAOK-1, a poorly understood enzyme that drives the tau protein tangles characteristic of Alzheimer's disease, along with a second compound, VU6080195, that activates the entire TAOK protein family. The inhibitor demonstrated that blocking TAOK-1 prevents the hyperphosphorylation of tau that disrupts neurons' internal transport systems, while the activator gives scientists an unexpected new tool to probe TAOK biology broadly for the first time. Because no selective chemical tools for this target existed before, researchers had been unable to study TAOK-1's precise role in disease progression; with both an inhibitor and an activator now in hand, the field gains a matched pair of instruments to map the pathway in detail. More than seven million Americans currently live with Alzheimer's, and the Vanderbilt team says the compounds point toward a concrete new avenue for small-molecule drug development.
Spain's bladeless wind turbine, with no gearbox to fail, edges toward a megawatt-scale prototype
Vortex Bladeless, a Spanish startup that has spent a decade developing a wind turbine with no blades or rotating parts, is drawing fresh attention this year as it works toward a 100-megawatt prototype design. Instead of spinning, the slender pole harnesses aeroelasticity: wind flowing past the cylinder creates oscillating vortices that make it sway back and forth, and a base-mounted linear alternator packed with neodymium magnets converts that motion directly into electricity. Because nothing rotates, the design needs no oil, grease or gearbox, which the company estimates cuts manufacturing costs by roughly 53% and operating costs by about 51% compared with a conventional turbine of similar height — while also being silent and posing no collision risk to birds. A peer-reviewed design study published in the journal Energies earlier this year proposed a new cylindrical-cam mechanism to further improve how efficiently the sway is converted into usable power, adding fresh engineering momentum to a concept that could open wind power to sites too small, noisy-sensitive or wildlife-sensitive for standard turbines.
Read more →Spain's bladeless wind turbine, with no gearbox to fail, edges toward a megawatt-scale prototype
Vortex Bladeless, a Spanish startup that has spent a decade developing a wind turbine with no blades or rotating parts, is drawing fresh attention this year as it works toward a 100-megawatt prototype design. Instead of spinning, the slender pole harnesses aeroelasticity: wind flowing past the cylinder creates oscillating vortices that make it sway back and forth, and a base-mounted linear alternator packed with neodymium magnets converts that motion directly into electricity. Because nothing rotates, the design needs no oil, grease or gearbox, which the company estimates cuts manufacturing costs by roughly 53% and operating costs by about 51% compared with a conventional turbine of similar height — while also being silent and posing no collision risk to birds. A peer-reviewed design study published in the journal Energies earlier this year proposed a new cylindrical-cam mechanism to further improve how efficiently the sway is converted into usable power, adding fresh engineering momentum to a concept that could open wind power to sites too small, noisy-sensitive or wildlife-sensitive for standard turbines.
Japanese recyclers hit 90% lithium recovery from old EV batteries, beating a 2030 target years early
A JX Metals Circular Solutions facility in Tsuruga, Japan, has achieved 90% lithium recovery from used EV batteries, nearly double the roughly 50% typical of prior industry processes, by substituting recovered lithium hydroxide for sodium hydroxide when converting thermally treated "black mass" into high-purity lithium powder ready for new battery production. The process also cuts the recycling operation's carbon footprint by about 40% compared with conventional methods, and the milestone already clears Japan's regulatory mandate of 70% lithium recovery by 2030 — three years ahead of schedule, with expanded operations set to begin in the second half of this fiscal year. The breakthrough addresses one of clean-energy's persistent bottlenecks: lithium supply for the coming wave of retiring EV batteries. Challenges remain, since only about 14% of Japan's end-of-life batteries currently enter official collection channels rather than being exported intact, but the higher-recovery process gives recyclers a much stronger economic case to capture more of that material domestically going forward.
Read more →Japanese recyclers hit 90% lithium recovery from old EV batteries, beating a 2030 target years early
A JX Metals Circular Solutions facility in Tsuruga, Japan, has achieved 90% lithium recovery from used EV batteries, nearly double the roughly 50% typical of prior industry processes, by substituting recovered lithium hydroxide for sodium hydroxide when converting thermally treated "black mass" into high-purity lithium powder ready for new battery production. The process also cuts the recycling operation's carbon footprint by about 40% compared with conventional methods, and the milestone already clears Japan's regulatory mandate of 70% lithium recovery by 2030 — three years ahead of schedule, with expanded operations set to begin in the second half of this fiscal year. The breakthrough addresses one of clean-energy's persistent bottlenecks: lithium supply for the coming wave of retiring EV batteries. Challenges remain, since only about 14% of Japan's end-of-life batteries currently enter official collection channels rather than being exported intact, but the higher-recovery process gives recyclers a much stronger economic case to capture more of that material domestically going forward.